5 Biotech Stocks in Focus

Good Morning PennyStockLive, here is what I am looking at today! Advance Cell Technology, Inc (OTC:ACTC) is a biotechnology company based in Marlborough, Massachusetts, USA.  The company is focusing in developing stem cell based technologies (adult and human embryonic both) and other methods and treatments in the area of regenerative medicines. In the area of embryonic and adult stem cell research the company has acquired, developed and maintains a portfolio of patents and patents applications. The company is heading towards final stage phase I clinical trials for the Retinal Pigment Epithelial (RPE) program. StemCells, Inc. (NASDAQ:STEM) is a biotechnology company which is engaged in discovering, developing and commercializing stem cell based technology for academic and industrial development. In research and development the company primarily focused on developing cellular medicine. The company has two flagship therapeutic product development programs namely The CNS Program, which targets in developing application for HuCNS-SC cells and human neural stem cell product candidate, and The Liver Program, which targets in application development for human liver engrafting cells. Recently, the company has expanded its SC proven product portfolio with launch of proprietary human cell detection antibodies. Aastrom Biosciences, Inc (NASDAQ: ASTM) is a pharmaceutical company which develops enhanced cellular therapies for use in the treatment of severe, chronic cardiovascular diseases. The Company ideology is to develop first-in-class treatments for critical limb ischemia and dilated cardiomyopathy – critical cardiovascular diseases that currently have limited or no treatment options. The Company has business relationship with companies like ioLife Solutions, Inc., Lonza Walkersville, Inc. and Invitrogen Corporation. Cell Therapeutics, Inc (NASDAQ: CTIC) is a biopharmaceutical company which develops, acquires and markets treatment of cancer. The Company has diversified itself into all types of drugs related to cancer with research, development, acquisition and in-licensing activities heavily applying on identifying and developing less hazardous ways to treat cancer. The Company has products like pixantrone, OPAXIO, brostallicin and bisplantinates in its product portfolio. In 2009, the company established a JV with Spectrum pharmaceutical to develop and commercialize Zevalin® (ibritumomab tiuxetan). Geron Corporation (NASDAQ: GERN) is a biopharmaceutical company with headquarters in California. The Company develops and markets drugs in the area of cancer and chronic degenerative diseases, including spinal cord injury, heart failure and diabetes. The Company was founded in 1990 and has around 100 employees working in the field of curing the cancer. The Company is currently developing an anti-cancer therapy based on telomerase inhibitors and telomerase therapeutic vaccines. The Company has a revenue base of $3.77 million. PSL Staff This corporate profile is provided for information purposes only and should not be used as the basis for any investment decision. We are neither licensed nor qualified to provide investment advice. We were not paid, nor do we hold a position in these stocks. We reserve the right to buy or sell ACTC, STEM, ASTM, CTIC and GERN at any time after this post.
Negocioenlinea
tdp2664Penny Stock Live